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Abstract
Background: Elevated pre-operative neutrophil: lymphocyte ratio (NLR) has been identified as a predictor of
survival in patients with hepatocellular and colorectal cancer. The aim of this study was to examine the prognostic
value of an elevated preoperative NLR following resection for oesophageal cancer.
Methods: Patients who underwent resection for oesophageal carcinoma from June 1997 to September 2007 were
identified from a local cancer database. Data on demographics, conventional prognostic markers, laboratory
analyses including blood count results, and histopathology were collected and analysed.
Results: A total of 294 patients were identified with a median age at diagnosis of 65.2 (IQR 59-72) years. The
median pre-operative time of blood sample collection was three days (IQR 1-8). The median neutrophil count was
64.2 × 10-9/litre, median lymphocyte count 23.9 × 10-9/litre, whilst the NLR was 2.69 (IQR 1.95-4.02). NLR did not
prove to be a significant predictor of number of involved lymph nodes (Cox regression, p = 0.754), disease
recurrence (p = 0.288) or death (Cox regression, p = 0.374). Furthermore, survival time was not significantly
different between patients with high (≥ 3.5) or low (< 3.5) NLR (p = 0.49).
Conclusion: Preoperative NLR does not appear to offer useful predictive ability for outcome, disease-free and
overall survival following oesophageal cancer resection.
Introduction
Human oesophageal carcinoma is considered one of the
most aggressive malignancies and is associated with a
poor prognosis [1]. Despite recent advancement in sur-
gical and oncological treatment the five year survival
remains very poor [2-4]. Oesophagectomy for oesopha-
geal cancer is a major operative intervention which car-
ries a high risk of complications. Hence any means of
predicting patients with an inherently poor prognosis or
high risk from surgery would be valuable in making
treatment recommendations.
Generally agreed prognostic factors for most gastro-
intestinal cancers include tumour size, marginal resec-
tion line involvement, lymph node metastases and
tumour differentiation [5]. During the last fifteen years
there has been debate about the interaction between
cancer and host inflammatory responses, in particular
whether cancer may alter regulation leading to further
DNA damage, promotion of angiogenesis, inhibition of
apoptosis and increased metastastic susceptibility
[6-10]. It is clear that the response of the immune sys-
tem plays a vital role in the control and progression of
many disease states including cancer. Simple measures
of immune responsiveness include simple routine bio-
chemical and haematological markers such as total and
differential leukocyte counts and C-reactive protein
(CRP), which have been proposed as diagnostic and
prognostic factors for a variety of cancers [11,12]. This
may permit a simple estimate of inflammatory
response to cancer which is easily assessed in everyday
clinical practice.
CRP is the most commonly used measure of systemic
inflammation in clinical practice, and has been shown to
be an independent predictor of survival in patients* Correspondence: farhan.rashid@nottingham.ac.uk
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undergoing resectional surgery for colorectal cancer
[13,14]. Haematological factors which have been scruti-
nised for prognostic value include lymphocyte count,
neutrophil count and neutrophil: lymphocyte ratio in
patients undergoing surgery for pancreatic ductal can-
cer, epithelial ovarian cancer and hepatic resection of
colorectal liver metastases [15,11,16]. The effect does
not appear to be restricted to major surgical interven-
tions as an elevated NLR has also been shown to predict
a poor outcome from interventional procedures for vas-
cular and cardiovascular diseases [17,18].
All patients undergoing oesophagectomy have preopera-
tive full blood counts taken routinely. The NLR can be cal-
culated easily from the data already available. NLR and
other inflammatory markers have been identified as a pre-
dictor of outcome in patients undergoing potentially cura-
tive resection for other gastrointestinal cancers, including
hepatocellular and colorectal carcinoma [13,15,16,19]. The
role of NLR in patients undergoing oesophageal cancer
resection does not yet appear to have been studied. The
present study was carried out to examine the hypothesis
that an elevated pre-operative NLR might prove a clini-
cally useful prognostic indicator for post-operative survival
and disease free interval following oesophageal cancer
resection. Prognosis would be assessed against standard
clinical and histopathological data.
Materials and methods
Study subjects
A retrospective analysis was carried out in accordance
with UK clinical research governance guidelines, and
was approved by our institutional audit department.
Patients who underwent surgical resection for oesopha-
geal cancer from June 1997 to September 2007 were
identified from our local database for oesophageal can-
cer. Demographic details, pre-operative staging data,
operation type, histopathological diagnosis, staging and
survival were extracted from the database. Pathological
staging was determined using the American Joint Com-
mittee on Oesophageal Cancer staging, which stages
tumours according to a revised tumour node metastasis
(TNM) system. All patients were followed up in out-
patient clinics at regular intervals. First follow up was
undertaken at 6 weeks following surgery and subse-
quently after 3 months, 6 months, 9 months, 1 year and
thereafter at every six months interval. Survival data was
analysed in October 2007.
Calculation of Neutrophil lymphocyte ratio
Routine full blood count (FBC) results were collected as
part of standard diagnostic and pre-operative protocols.
The NLR was calculated as a simple ratio between the
absolute neutrophil and the absolute lymphocyte counts,
as provided from the differential white cell count output
from a standard Coulter® counter (Model, XE2100, Sys-
mex, Japan).
Statistical methods
The distribution of continuous variables was tested for
normality using the Kolmogorov-Smirnov test and Q-Q
plots. All continuous variables were skewed therefore
the results were reported as medians {Interquartile
range (IQR)}. The Spearman’s correlation coefficient
was used to assess the association between continuous
variables. The Mann-Whitney U test was calculated for
comparison of two groups and the Kruskal-Wallis test
was used to compare more than two groups. Cox
regression and Kaplan-Meier analysis was utilised to
assess the predictive value for NLR, neutrophil and lym-
phocyte counts for hazard of death. The Kaplan-Meier
curves were compared using the Log Rank test. The
Cox regression models were constructed using the For-
ward: Likelihood ratio method with p value less than
0.05 as the entry criterion to the model for the indepen-
dent variables. The hazard risk (HR) from the Cox
Regression analysis was not presented for non signifi-
cant specific variables that were tested. The Chi-Square
test was used to test the association between NLR
groups (Cut-offs of 3, 3.5, 4 and 5) and recurrence,
Table 1 Demographics and preoperative haematology
results from patients with resected oesophageal cancer.
Demographics
No of patients identified 294
Male/Female 235:59
Median age (IQR) 65.2 (59-72) years
Overall median survival (IQR) 22 (14-90) months
Histological subtypes
Adenocarcinoma 238(81%)
Scquamous cell carcinoma 50(17%)
Preoperative FBC available 294
Median neutrophil count (IQR) 64.2 × 10-9/litre, (58-71)
Median lymphocyte count (IQR) 23.9 × 10-9 /litre, (17-30)
Neutrophil lymphocyte ratio(IQR) 2.69,(1.95-4.02).
Median timing of preoperative FBC
(IQR)
3 (1-8)
Neutrophilia (> 7.5×106/ml) 265(94%)
Lymphocytopenia (< 1.0 ×106/ml) 57(20%)
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Figure 1 NLR median and IQR box plot for three oesophageal cancer groups.
Figure 2 NLR value and TNM nodal status.
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Tumour (T)-stage, Nodal (N) stage and histological sub-
type of cancer.
SPSS version 16.0 was used for statistical analysis
(SPSS, Woking, Surrey UK). An alpha probability (p
value) of less than 5% (0.05) was considered significant.
Results (Table 1)
Of 294 patients studied, there were 235 males and 59
females. The median age at diagnosis was 65.2 years
(IQR 59-72). There were 238 adenocarcinomas (81%),
50 squamous cell cancers (17%) and 6 other cancers
(2%) comprising 2 gastrointestinal stromal tumours,
one oat cell cancer and three undifferentiated oesopha-
geal tumours. The median time for pre-operative FBC
sample collection was 3 days, (IQR: 1 - 8). No patient
exhibited clinical signs of sepsis in the pre-operative
period.
Neutrophil: lymphocyte ratio (Table 1)
The overall median neutrophil count was 64.2 × 10-9/
litre, IQR 58.6-71.0, the median lymphocyte count 23.9
× 10-9 /litre, IQR 17.8-30.0 and the NLR was 2.69, IQR
1.95-4.02).
NLR as a predictor of death
NLR was not a significant predictor of hazard of death
(Cox Regression analysis, p = 0.374).
NLR and age
There was no significant correlation between age and
NLR (r = 0.094, p = 0.117, Spearman’s correlation
coefficient).
Neutrophil: lymphocyte ratio in cancer subsets (Figure 1)
(Table 1)
NLR values were not significantly different between
patients within the two different types of cancer (adeno-
carcinoma 2.69, IQR 1.32-3.96 and squamous cell carci-
noma 2.98, IQR 2.10-4.10. Mann Whitney U test p =
0.740) (Figure 1).
NLR and nodal status
NLR values were not significantly different between
TNM subsets of lymph node status. The median NLR in
pN0 (no lymph node metastasis) patients was 2.69, IQR
1.75-4.10 and in pN1 (regional lymph node metastasis)
patients was 2.69, IQR 2.08-3.93, which was not signifi-
cantly different (p = 0.592). (Figure 2). NLR value was
not significantly correlated with either the lymph node
yield, (r = 0.28, p = 0.644) nor with the involved lymph
node (r = 0.42, p = 0.493) (Figure 3).
NLR and T stage
There was no relationship between different NLR cut off
values (3, 3.5,4 and 5) and the depth of invasion or T
stage (p values of 0.624, 0.937, 0.866 and 0.522
respectively).
Figure 3 NLR and ratio of involved to total lymph node yields.
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NLR and disease recurrence (Table 2)
There was no significant relationship between NLR
values and the probability of disease recurrence (recur-
rence free 2.82 IQR1.78-4.07, P = 0.82, and recurrent
disease 2.79 IQR 2.12-4.28, P = 0.288).
NLR vs Survival (Figure 4, 5, 6 &7)
NLR was grouped into different cut-off points (3, 3.5, 4
and 5) to find whether there was any significant differ-
ence in survival. There was no significant difference in
survival between patients with NLR values of greater
than or equal to 3.5 and those with an NLR of less than
3.5. The median overall survival was 22 months, IQR 14-
90. Survival time was not statistically significantly differ-
ent between groups with NLR ≥ 3.5 and those with < 3.5
(p = 0.49). Similarly, the choice of other NLR cutt offs (3,
4 and 5) did not show any significant difference in survi-
val (p values of 0.340, 0.680 and 0.868 respectively).
NLR and preoperative chemotherapy
Fourty four patients had preoperative chemotherapy as
compared to 250 patients who underwent surgery as
first line treatment without neo-adjuvant chemotherapy.
The neutrophil count for patients with chemotherapy
(Median 57.8, (49-64.7)) was lower than patients without
chemotherapy (Median 65.3, (60-72), p < 0.001). How-
ever, the patients with chemotherapy had higher lym-
phocyte count (Median 31, 22-37) as compared to those
without preoperative chemotherapy (Median 22.7 (17-
28.6), p < 0.001). Median NLR of those who had che-
motherapy was 1.86 (IQR, 1.3-2.9) and those without
chemotherapy was 2.8 (IQR, 2.1-4.3) (p < 0.001). There
was no survival difference in patients with or without
chemotherapy (p = 0.323). In addition, adjusting for
NLR, there was no difference in survival for patients
who had received preoperative chemotherapy as com-
pared to those without neoadjuvant chemotherapy (p =
0.280, Cox regression analysis with interaction term).
NLR cut off values and type of cancer (Table 3)
Different values of NLR have been used as a predictor of
prognosis [15]. A cut off value 3.5 has also not shown
any significant association between two sub-types of
oesophageal cancer and NLR values.
Discussion
Leukocytes were first discovered in malignant tissue spe-
cimens by the pathologist Rudolf Virchow about 150
years ago [6]. Inflammation not only plays a vital role in
Table 2 NLR values and disease recurrence
NLR IQR P-Value
Recurrence Free 2.82 1.78-4.07 0.288
Recurrence 2.79 212-4.28 0.288
Figure 4 Survival for patients with NLR < 3.5 and > = 3.5(Censored = alive) (p = 0.49).
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Figure 5 Survival for patients with NLR < 4 and > = 4(Censored = alive) (p = 0.680).
Figure 6 Survival for patients with NLR < 3 and > = 3(Censored = alive) (p = 0.340).
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development but also remains very important in pro-
gression of various malignant disease processes includ-
ing gastrointestinal tract [20-22] and liver cancers [23].
Neutrophilia has been associated with malignancy,
although the cause is not completely understood. How-
ever, it is a multifactorial process. Research has
confirmed a link between the inflammatory microenvir-
onment of a tumour, and systemic responses induced by
the tumour. The presence of T-cells in a tumour pro-
vides an indication of significant local immune
responses [24,25]. For many types of cancer, lymphocy-
topaenia indicates a generalized state of immunodepres-
sion [26], and survival appears to be adversely
influenced by depressed immune function. There may
be a marked decrease in CD-4 helper lymphocytes and
an increase in CD-8 suppressor lymphocytes, signifying
depression of innate cellular immunity [27]. Depression
in T-cell function may attenuate the tumour specific
response. Major surgery in cancer patients is known to
reduce lymphocyte metabolism, as measured by adeno-
sine triphosphate production, which leads to functional
impairment [28]. In addition, the microenvironment
within the tumour can also influence on the invading
leukocytes to enhance angiogenesis, invasion, motility
and viability [6,7,29,30].
The malignant process also produces myeloid growth
factors as part of a paraneoplastic syndrome and this
may be one of the causes of neutrophilia. In addition,
another factor granulocyte colony stimulating factor
produced by the malignant cells has also been attributed
to be the cause of neutrophilia because of its action on
bone marrow granulocytic cells [31-35]. Apart from the
production of myeloid growth factors, cancer inflamma-
tion and associated neutrophilia have also been asso-
ciated with the release of IL-6 (interleukin-6) and TNF-
a (Tumour necrosis factor-a) [36-39].
Some variations have been observed in different cancers.
Patients with pancreatic ductal adenocarcinoma have been
identified as having more marked lymphocytopenia preo-
peratively and postoperatively, when compared with
patients having gastric and colorectal carcinoma [39]. Pre-
vious studies have suggested different NLR values as a
prognostic marker [15,17,40]. The preoperative NLR of
greater than 5 was elevated in only around 15% of our
patients as compared to 32% in the study published by
Walsh et al in patients with colorectal cancer. In addition,
majority of the patients (94%) in our study had neutrophi-
lia as compared to near normal neutrophil count in most
of the patients undergoing resection of pancreatic ductal
adenocarcinoma [16].
Figure 7 Survival for patients with NLR < 5 and > = 5(Censored = alive) (p = 0.868).
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The oesophageal tumour occurs more frequently in
males and such tumours have a worst prognosis when
compared to their female counterparts [1]. The gender
effects on the changes of circulating subtypes of white
cells, the differences in endocrine reactions to the nature
of the stress have been studied and certain variations in
immune response between males and females have also
been reported [41-44]. The females have shown a more
immunocompromised response as compared the male
patients [41]. Although the immune response is multi-
factorial, the male predominance of oesophageal cancer
(male to female ratio of 4:1 in this study) may be one of
the reasons why NLR does not work as a predictor in
our study as compared to the other studies.
All these factors may explain the variance in the
results of our study compared to others undertaken in
different cancers.
Inflammation is known to play a role in some colorectal
cancers. This includes causation, with ulcerative colitis
known to involve recurrent ulceration, epithelial regenera-
tion dysplasia and in some cases malignant change. Oeso-
phageal cancer can be preceded by Barrett’s oesophagus,
also a chronic inflammatory process involving metaplasia
(figure 8a &8b). However the majority of gastrointestinal
tract cancers do not arise as a result of overt acute or
chronic inflammation. Nevertheless, cancer invokes a host
inflammatory reaction as a consequence.
Immunosurveillance for cancer fails as humans age
[45,46], and this may also explain changes in neutrophil
and lymphocyte counts in oesophageal cancer, predomi-
nantly a disease of older patients. 58% of our patients
were over 60 years of age, in keeping with most pub-
lished series.
Table 3 Association between the type of cancer and NLR





> = 3.5 Total
Adeno n 165 71 236
% 81.3% 80.7% 81.1%
Squamous N 34 15 49
% 16.7% 17.0% 16.8%
Figure 8 a Oesophageal cancer histopathology: there is marked dysplastic change but little polymorphic infiltration. 8b: Colonic
tumour with excessive polymorphic infiltration but little dysplasia.
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Our cohort includes only those oesophageal cancer
patients who had resectable disease and underwent sur-
gery and does not include those who underwent pallia-
tive treatment. This exclusion of the patients with
metastatic disease remains a shortcoming of the study.
In conclusion, the present study failed to confirm that
NLR was a significant predictor of survival, recurrence
and nodal involvement following resection for oesopha-
geal cancer.
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